FOR IMMEDIATE RELEASE:

ABMC EARNS FEDERAL SUPPLY SCHEDULE CONTRACT
GSA Contract Opens Doors to Federal Business for Drug Test Manufacturer

KINDERHOOK, NY -- August 6, 2024 -- American Bio Medica Corporation (NASDAQ: ABMC) today announced that it has been awarded a GSA Federal Supply Schedule Contract from the General Services Administration of the United States Government.

This contract award simplifies the ordering process for Federal agencies in search of drug testing products and services, in effect averting the requirement for these agencies to advertise or open the bidding process for certain programs, and allowing them to place orders directly with ABMC.

Federal agencies in need of drug testing products and services are now able to order ABMC resources under a purchase order that references this award contract, without the need for opening programs to solicitations from other manufacturers. The award is granted under contract number GS-07F-0277L; contract prices are available on the GSA Advantage shopping system at www.gsaadvantage.gov, hosted by the General Services Administration.

"This award places ABMC's drug testing resources in an elite class of drug testing suppliers, and it signifies that we maintain high levels of performance," said Robert L. Aromando Jr., chief executive officer and chairman of American Bio Medica. "This is an important milestone for our company, because we have never had a GSA contract before, and we are very optimistic about the doors this will open to new government business, specifically with the federal probation and pretrial segment. We see significant revenue opportunities on the near horizon."

About American Bio Medica Corporation

American Bio Medica Corporation develops, manufactures and markets inexpensive, accurate, on-site drugs-of-abuse diagnostic kits, sprays and support services worldwide. The company's global distributors target the workplace, physicians, corrections, clinical, and educational markets. In addition to Drug Detector, ABMC markets Rapid Drug Screen™ which is designed to test individuals and is proven to correlate greater than 99% with the standard laboratory screening test.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risk and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, intellectual property rights and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.


Contact:
     American Bio Medica Corporation, Kinderhook
     Melissa A. Decker, 800/227-1243
     Fax: 518/758-8171
     Email: melissa@americanbiomedica.com
     Web: www.americanbiomedica.com